达格列净与二甲双胍单用及联用治疗妊娠期糖尿病后超重女性的随机试验
本研究为前瞻性单盲随机对照试验,纳入66例近12个月内患妊娠期糖尿病且BMI>25的女性,随机接受达格列净、二甲双胍或两药联合治疗24周。结果显示,联合治疗在体重、腰围、血糖及心血管代谢指标改善上优于二甲双胍单药,且达格列净单药在血脂谱方面也优于二甲双胍。
要点
- 联合治疗较二甲双胍单药显著降低体重、腰围和腰高比,并改善血糖及胰岛素敏感性。
- 达格列净单药及联合治疗在升高高密度脂蛋白、降低甘油三酯和改善糖耐量后血糖波动方面优于二甲双胍。
- 仅联合治疗显著改善葡萄糖负荷后的早期胰岛素反应。
核心结论
- 在近期有妊娠期糖尿病史的超重或肥胖女性中,达格列净联合二甲双胍治疗24周对体重、腰围及血糖、心血管和代谢指标的正向效应大于二甲双胍单药治疗。
研究设计与样本
- 前瞻性、单盲、随机、门诊临床试验,3个平行治疗组,共纳入66例年龄18-45岁、近12个月内患妊娠期糖尿病且BMI>25的女性,随机接受达格列净、二甲双胍或达格列净-二甲双胍联合治疗24周。
主要发现
- 与二甲双胍单药相比,达格列净-二甲双胍联合治疗显著降低体重、腰围和腰高比,并改善血糖及口服葡萄糖耐量试验衍生的胰岛素敏感性指数。
- 达格列净单药和联合治疗在升高高密度脂蛋白水平、降低甘油三酯浓度、降低甘油三酯与高密度脂蛋白胆固醇比值以及改善口服葡萄糖耐量试验后血糖波动方面均优于二甲双胍。
- 仅达格列净-二甲双胍联合治疗较单药治疗显著改善葡萄糖负荷后的早期胰岛素反应。
临床怎么用
- 对于近期有妊娠期糖尿病史的超重或肥胖女性,可考虑使用达格列净联合二甲双胍以更全面地改善体重、血糖及心血管代谢指标。
局限性
- 研究完成率为74%(49例完成),样本量较小(n=66),可能影响结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with a history of gestational diabetes mellitus are at a substantially increased risk of gestational diabetes mellitus recurrence and type 2 diabetes. Weight gain, particularly increased central adiposity after delivery, is strongly associated with deterioration of pancreatic beta cell compensation for insulin resistance. Weight management after gestational diabetes mellitus could have a significant benefit in these women who are at a high risk of developing type 2 diabetes. OBJECTIVE: This study aimed to evaluate the treatment efficacy of dapagliflozin and metformin, alone and in combination, on body weight and anthropometric, cardiovascular, and metabolic parameters in overweight women with a recent history of gestational diabetes mellitus. STUDY DESIGN: This was a prospective, single-blind, randomized, outpatient clinical trial with 3 parallel treatment groups. Overweight or obese (body mass index>25) females (n=66; ≥18-45 years) with gestational diabetes mellitus in pregnancy in the past 12 months were randomized in a single-blind manner to dapagliflozin, metformin, or dapagliflozin-metformin for 24 weeks. Body weight, height, body mass index, waist circumference, waist-to-height ratio, and blood pressure were determined at baseline and trial completion. Oral glucose tolerance tests were performed at baseline and 24 weeks to assess glycemia and mean blood glucose and calculate insulin sensitivity and secretion measures. Plasma lipid fractions, thyroid-stimulating hormone, and liver enzymes were also assessed in the fasting sample at the beginning and completion of the study trial. RESULTS: The study was completed by 49 participants (74%). Significant reduction of weight, waist circumference, and waist-to-height ratio and improved glycemia and insulin sensitivity index derived from oral glucose tolerance test were found with dapagliflozin-metformin vs metformin monotherapy. Both dapagliflozin and dapagliflozin-metformin therapy were superior to metformin in increasing high-density lipoprotein levels, reducing triglyceride concentrations, lowering the triglyceride-to-high-density lipoprotein cholesterol ratio, and improving glucose excursion after an oral glucose tolerance test. The early insulin response to a glucose challenge significantly improved with only dapagliflozin-metformin compared with single-drug treatments. CONCLUSION: This is the first report comparing the efficacy of a sodium-glucose cotransporter 2 inhibitor alone and in combination with metformin in this patient population. We found that combination dapagliflozin-metformin treatment over a 24-week period had a greater positive effect on body weight, waist circumference, and glycemic, cardiovascular, and metabolic parameters than metformin monotherapy in overweight or obese at-risk women with a recent history of gestational diabetes mellitus.
引用
- Elkind-Hirsch KE, Seidemann E, Harris R, et al. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. Am J Obstet Gynecol MFM. 2020. PMID: 33345876. doi:10.1016/j.ajogmf.2020.100139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。